Clovis' Rociletinib Facing Three-Year Delay If FDA Follows Panel's Lead

Lung cancer drug gets thumbs down for accelerated approval from advisory committee, meaning FDA's thumbs up might have to wait for results from 900-patient confirmatory trial, which some panelists said should be redesigned to provide more clarity around dosing.